Cargando…
Letter Regarding “Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios”
Autores principales: | Rico-Fontalvo, Jorge, Daza-Arnedo, Rodrigo, Raad-Sarabia, Maria, Restom-Arrieta, José, Bohórquez-Rivero, José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091584/ https://www.ncbi.nlm.nih.gov/pubmed/35571005 http://dx.doi.org/10.1016/j.ekir.2022.02.025 |
Ejemplares similares
-
Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022) -
Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios
por: Agarwal, Rajiv, et al.
Publicado: (2022) -
Molecular Mechanisms of Diabetic Kidney Disease
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022) -
Coverage and the Interpretation of Classical Confidence Intervals
por: James, Frederick E
Publicado: (2005) -
Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
por: Daza-Arnedo, Rodrigo, et al.
Publicado: (2021)